SGMO
SGMO
NASDAQ · Biotechnology

Sangamo Therapeutics Inc

$0.40
+0.05 (+13.15%)
As of Feb 8, 2:08 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 23.05M 23.70M 20.49M
Net Income -3,594,155 -3,056,252 -2,992,966
EPS
Profit Margin -15.6% -12.9% -14.6%
Rev Growth +13.8% +16.7% +8.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 65.30M 61.71M 62.11M
Total Equity 85.25M 96.81M 91.91M
D/E Ratio 0.77 0.64 0.68
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -5,194,179 -4,785,189 -3,856,552
Free Cash Flow -2,246,925 -2,136,953 -2,270,748